Amicus Therapeutics Inc (FOLD)
HEALTH CARE:
PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS
Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule, orally-administered drugs, known as pharmacological chaperones, for the treatment of a range of human genetic diseases. The pharmacological chaperone technology involves the use of small molecules to restore biological activity in cells by binding to a misfolded protein caused by a genetic mutation. The company is targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Its lead compound includes Amigal, which is in Phase II clinical trials is used for the treatment of Fabry disease that causes kidney failure, cardiac abnormalities, and neurological complications. The company is also developing AT2101 for the treatment of Gaucher disease, which causes an enlarged liver and spleen, low levels of red blood cells and platelets, bone pain, and fractures; and AT2220 for the treatment of Pompe disease, which causes muscle weakness primarily affecting breathing, mobility, and heart function. The company has a strategic collaboration with Shire Human Genetic Therapies, Inc. to jointly develop pharmacological chaperone compounds for lysosomal storage disorders.
| Market Cap | 3.336 Billion | Shares Outstanding | 258.788 Million | Avg 30-day Volume | 1.575 Million |
| P/E Ratio | Dividend Yield | EPS | -1.14 | ||
| Price/Sales | 14.699 | Price cash flow ratio | Price free cash flow ratio | -12.3 | |
| Book Value | 1.39 | Price to Tangible Book | 23.8 | Alpha | 0.0 |
| Short Interest Ratio | % Short Interest to Float | R-squared | 0.091219 | ||
| BETA | 1.17512 | 52-week High/Low | 16.13 / 6.25 | Stddev | 0.166245 |
| Q2 2020 | All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|---|---|---|---|---|---|
| In top 10: | 7 | 6 | 16.67% | 5 (0.33%) | 4 (0.26%) | 25.0% |
| Funds Holding: | 224 | 202 | 10.89% | 73 (4.76%) | 65 (4.16%) | 12.31% |
| 13F shares: | 277.401 Million | 279.74 Million | -0.84% | 122.921 Million | 124.382 Million | -1.17% |
| % Ownership | 47.7059 | 48.2976 | -1.23% | |||
| New Positions: | 43 | 30 | 43.33% | 18 | 15 | 20.0% |
| Increased Positions | 71 | 66 | 7.58% | 21 | 18 | 16.67% |
| Closed Positions | 17 | 50 | -66.0% | 9 | 24 | -62.5% |
| Reduced Positions | 74 | 72 | 2.78% | 25 | 25 | 0.0% |
| Total Calls | 2.878 Million | 1.446 Million | 99.06% | 352.1 Thousand | 202.5 Thousand | 73.88% |
| Total Puts | 269.501 Thousand | 433.375 Thousand | -37.81% | 114.7 Thousand | 121.8 Thousand | -5.83% |
| PUT/CALL Ratio | 0.09 | 0.3 | -70.0% | 0.33 | 0.6 | -45.0% |
| 1 hedge funds and active managers as identified by whalewisdom.com through public filings. | ||||||
- Caxton Corp added to its Strongbridge Bio stake. The biopharma stock is Bruce Kovner's #2 position. 09/22/2020
- An effective drug for Alzheimer's would be huge. After a positive Phase 2 study, an analyst upgrades and Cassava Sciences insiders buy. 09/18/2020
- Yield10 insider Jack Schuler bought $1.5M of YTEN on Aug. 26. The stock soared 53% on Sept 10. 09/12/2020
- Camping World insider Lemonis has been on a buying spree. JPMorgan upgrades CWH and the stock pops 10%. 09/08/2020
- Peloton’s Stock Rises Benefits Despite Pandemic 09/21/2020
- Hedge Funds Are Betting Big On A Rebound In Hilton’s Stock 09/14/2020
- Adobe’s Strong Growth Sends the Shares Soaring 09/07/2020
- Zoom’s Stock Soars as Hedge Funds Move-In 08/31/2020
- Apple’s Historic Rise 08/24/2020
- Visa Navigates Pandemic’s Bumpy Ride 08/17/2020
